RNA, U4atac small nuclear 18, pseudogeneGenealiases: []
Q-omics provides the consensus-scored RNU4ATAC18P profile across patient tissues and cancer cell-line models. RNU4ATAC18P expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, RNU4ATAC18P is differentially expressed in 8, with the highest sampling consensus in LIHC. Additionally, RNU4ATAC18P RNA expression shows 17,351 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight KIRC, LIHC, and UVM as cancer lineages where RNU4ATAC18P shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RNU4ATAC18P — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RNU4ATAC18P survival associations across molecular data types. RNU4ATAC18P RNA expression shows survival associations in the most cancer types (24). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RNU4ATAC18P RNA expression–survival associations across cancer types. High RNU4ATAC18P expression shows unfavorable associations in KIRC, THCA and ACC, but favorable associations in HNSC, BLCA and PAAD. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for RNU4ATAC18P RNA expression.
This table summarizes RNU4ATAC18P tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8. The strongest signals are observed in LIHC for RNA.
This table ranks reproducible tumor–normal expression differences for RNU4ATAC18P. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RNU4ATAC18P shows lower tumor expression in THCA, BRCA and KICH and higher tumor expression in LIHC, HNSC and KIRC. The LIHC box plot shows higher RNU4ATAC18P RNA expression in tumor versus normal tissue (log2 FC = +0.534, t-test p < 0.001).
This table shows molecular features associated with RNU4ATAC18P in patient tissues and cancer cell lines. In patient samples, RNU4ATAC18P shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set.
